Flaharty KK[au] - Search Results

Year	Number of Results
1989	3
1990	2
1991	2
1992	1
1993	1
2000	1
2014	1
2015	1
2016	1
2024	0

1

Epoetin: human recombinant erythropoietin.

Flaharty KK, Grimm AM, Vlasses PH. Flaharty KK, et al. Clin Pharm. 1989 Nov;8(11):769-82. Clin Pharm. 1989. PMID: 2680241 Review.

2

Hepatotoxicity associated with amiodarone therapy.

Flaharty KK, Chase SL, Yaghsezian HM, Rubin R. Flaharty KK, et al. Pharmacotherapy. 1989;9(1):39-44. doi: 10.1002/j.1875-9114.1989.tb04102.x. Pharmacotherapy. 1989. PMID: 2646621 Review.

3

Latisse (bimatoprost) for enhancement of eyelashes.

Flaharty PM, Flaharty KK, Gorman L. Flaharty PM, et al. Among authors: flaharty kk. Insight. 2014 Summer;39(3):24-6. Insight. 2014. PMID: 25195339 No abstract available.

4

Clinical pharmacology of recombinant human erythropoietin (r-HuEPO).

Flaharty KK. Flaharty KK. Pharmacotherapy. 1990 Mar-Apr;10(2 ( Pt 2)):9S-14S. Pharmacotherapy. 1990. PMID: 2345710

5

Cardiopulmonary events during hemodialysis: effects of dialysis membranes and dialysate buffers.

Munger MA, Ateshkadi A, Cheung AK, Flaharty KK, Stoddard GJ, Marshall EH. Munger MA, et al. Among authors: flaharty kk. Am J Kidney Dis. 2000 Jul;36(1):130-9. doi: 10.1053/ajkd.2000.8285. Am J Kidney Dis. 2000. PMID: 10873882 Clinical Trial.

6

Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men.

Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, Vlasses PH. Flaharty KK, et al. Clin Pharmacol Ther. 1990 May;47(5):557-64. doi: 10.1038/clpt.1990.76. Clin Pharmacol Ther. 1990. PMID: 2188770 Clinical Trial.

7

Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers.

Morganroth J, Flaharty KK, Parisi S, Moresino C. Morganroth J, et al. Among authors: flaharty kk. Support Care Cancer. 2016 Feb;24(2):621-627. doi: 10.1007/s00520-015-2822-6. Epub 2015 Jun 26. Support Care Cancer. 2016. PMID: 26111957 Free PMC article. Clinical Trial.

8

Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration.

Besarab A, Flaharty KK, Erslev AJ, McCrea JB, Vlasses PH, Medina F, Caro J, Morris E. Besarab A, et al. Among authors: flaharty kk. J Am Soc Nephrol. 1992 Mar;2(9):1405-16. doi: 10.1681/ASN.V291405. J Am Soc Nephrol. 1992. PMID: 1627763 Clinical Trial.

9

Fanconi's syndrome due to ifosfamide.

Beckwith C, Flaharty KK, Cheung AK, Beatty PG. Beckwith C, et al. Among authors: flaharty kk. Bone Marrow Transplant. 1993 Jan;11(1):71-3. Bone Marrow Transplant. 1993. PMID: 8431714

10

Probenecid enhances central nervous system uptake of 2',3'-dideoxyinosine by inhibiting cerebrospinal fluid efflux.

Galinsky RE, Flaharty KK, Hoesterey BL, Anderson BD. Galinsky RE, et al. Among authors: flaharty kk. J Pharmacol Exp Ther. 1991 Jun;257(3):972-8. J Pharmacol Exp Ther. 1991. PMID: 1904495

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year